Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

This phase II trial studies how well focal radiation therapy with stereotactic body radiation therapy (SBRT) or high-dose rate (HDR) brachytherapy works in treating patients with low or intermediate-risk prostate cancer. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. HDR brachytherapy uses high doses of radiation to target these tumor cells. Giving focal radiation therapy with SBRT or HDR brachytherapy may target dominant tumor cells while sparing the reminder of the prostate or surrounding normal organs and ultimately reduce side effects while maintaining disease control.

Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04399824.

Trial PhasePhase II

Trial Typetreatment

Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center

Principal InvestigatorAlan C. Lee

• Primary ID20-000051
• Secondary IDsNCI-2020-01464
• ClinicalTrials.gov IDNCT04399824